Select all that apply
Select all that apply
Leveraging efficiency from cell line development to clinical manufacturing of monoclonal antibodies
The number of FDA-approved monoclonal antibodies (mAbs) continues to grow, while those in late-stage development rose more than 30% between 2021 and 2022.
Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery
Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality...
Antibody-based drug discovery at the speed of light
The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.
Comprehensive mRNA Solutions
Partner with Curia for combined expertise, speed and reliability to support the research, development and manufacturing of your mRNA product.
Casual Nexus – Episode Six: Biocatalysis, Biosynthesis and Fermentation - The Evolution of Chemistry via Biology
Presented by Pete Michels, Ph.D., Head of Global Fermentation, Curia Jose Luis Barredo, Ph.D., Director, Engineering Services, Curia Listen in as our experts discuss: A brief history of biocatalysis with a look at its current and futur...
Casual Nexus – Episode Five: Saving Time in Hit-to-Lead Investigations
Presented by Mark Wolf, Ph.D., Section Head, Medicinal Chemistry - Curia Doug Kitchen, Ph.D., Section Head, CADD, Medicinal Chemistry - Curia Listen in as our experts discuss: The importance of a strong hit-to-lead program in drug d...
Hit-to-Lead Optimization Strategy in Drug Discovery
In vitro biochemical assays make possible the high throughput screening (HTS) of large compound libraries. A successful HTS campaign is typically viewed as one that identifies large numbers of diverse chemical series hits as potential starting points...
Drug Polymorphism: A Key Consideration for API Development
Xtalks spoke with Dr. Steef Boerrigter, a senior research scientist at Curia and an expert at materials science. He has extensive experience with experimental screening technologies for polymorphs, salts and cocrystals and has developed computationa...
Key Considerations for End-to-End Primary Packaging Solutions for Pharmaceuticals & Devices
The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...
Solid Form Selection in Drug Development
Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...
Creating Compound Screening Libraries that Address the Challenges of Drug Discovery
From target discovery through launching a finished product to market, developing a new drug is a complex process which takes on average 10-15 years and costs around 2.6 billion dollars. Early on, this process often involves a high-throughput screenin...
Comparison of Neisseria gonorrhoeae minimum inhibitory concentrations obtained using agar dilution versus microbroth dilution methods
With increasing antibiotic resistance observed amongst clinical isolates of Neisseria gonorrhoeae, the second most prevalent sexually transmitted bacterial disease in the United States, there is still a need for antimicrobial susceptibility testing...